Canopy Growth (Nasdaq: $CGC) Stock Hub: FY2026 Reset, MTL Cannabis, Medical Growth and the U.S. Schedule III Option

Executive Summary

Canopy Growth remains one of the most recognizable cannabis tickers in North America, but the reason to follow $CGC in 2026 is very different from the reason traders followed it during the original cannabis mania. The old story was market access, legalization optimism and brand land-grab. The current story is narrower, cleaner and more demanding: can a smaller, recapitalized Canopy convert medical cannabis scale, MTL Cannabis assets, selected adult-use innovation and international medical demand into a credible path toward operating break-even?

Fiscal 2026 gave the market a mixed but materially updated picture. Consolidated net revenue reached C$284.6 million for the year, up 6% versus FY2025, while Q4 FY2026 net revenue was C$71.2 million, up 10% year over year. Cannabis net revenue was stronger than the consolidated headline, rising 15% for FY2026 and 20% in Q4, helped by Canadian medical growth, adult-use product innovation and a Q4 rebound in international markets after earlier European supply constraints. At the same time, Storz & Bickel, historically one of Canopy’s higher-quality assets, declined 14% for the full year and 14% in Q4, pressured by consumer softness, U.S. import tariffs and comparison against stronger prior-year periods.

The balance sheet is no longer the same existential problem it was during the worst phase of the cannabis unwind. Canopy ended FY2026 with C$364.7 million in cash and cash equivalents, C$217.1 million of long-term debt, and a stated net cash position of C$131.3 million after a strategic recapitalization. Free cash outflow improved from C$176.6 million in FY2025 to C$69.1 million in FY2026. Adjusted EBITDA remained negative at a C$20.2 million loss for the year, but the company is guiding toward positive adjusted EBITDA during FY2027, with management expecting improvements to be more visible in the second half of the fiscal year as MTL integration progresses.

That is the bull case in one sentence: Canopy has finally bought itself time, refocused the operating base, added MTL Cannabis, and now has a measurable FY2027 profitability target. The bear case is equally simple: the company is still lossmaking, shares outstanding have increased sharply, Storz & Bickel is not currently growing, prior-period financial statements required restatement for warrant accounting, and the U.S. optionality remains structurally complicated because Canopy USA is unconsolidated and dependent on legal, exchange and regulatory permissibility.

Quick Snapshot

What Canopy Growth Is Today

Canopy Growth is a cannabis company, but the label is too broad to describe the current investment story. It is better understood as a three-part platform: Canadian cannabis, international medical cannabis and devices, with a separate U.S. THC option sitting through Canopy USA. The company sells medical and adult-use cannabis products in Canada, serves medical patients through channels such as Canada House Clinics and Abba Medix, owns or licenses brands including Tweed, 7ACRES, DOJA, Deep Space, Deelish, Claybourne, MTL Cannabis, Low Key by MTL and R’belle, and owns Storz & Bickel, the German vaporizer business.

This matters because the old “Canadian LP” framework is incomplete. A simple cannabis cultivation story would mostly depend on wholesale prices, provincial distribution, excise taxes and retail share. Canopy still faces all of those issues, but management is now trying to build a more balanced platform around medical cannabis patients, higher-quality flower supply, consumer product innovation, European medical growth, and a U.S. option that could become more valuable if federal cannabis policy continues to shift.

The MTL Cannabis acquisition changed the shape of the company. Canopy completed the transaction in March 2026, acquiring all issued and outstanding MTL shares. Management framed the deal as a way to create Canada’s leading medical cannabis platform by revenue, strengthen premium flower supply, add disciplined operating assets and support the company’s FY2027 adjusted EBITDA objective. The transaction also brought MTL leadership into Canopy’s operating structure, including Michael Perron as Chief Operating Officer.

For investors and traders, that makes CGC a turnaround proof story. It is no longer enough for the company to say cannabis is a large future market. The market has heard that before. The burden now is execution: stronger revenue quality, real gross-margin stability, lower cash burn, less reliance on equity issuance, and a clearer path from brand relevance to operating cash generation.

Why $CGC Matters Now

The reason $CGC deserves renewed attention in July 2026 is that the major February setup has already expired. The company has reported Q4 and FY2026 results, completed MTL Cannabis, filed the comprehensive annual report containing restated prior-period financials, and entered a cannabis-policy window where the U.S. DEA hearing has become the central sector catalyst.

In other words, the debate has moved from “Canopy reports Q4 soon” to “Canopy has now shown the FY2026 reset, and FY2027 must prove the model.” That is a very different equity setup. The market is no longer waiting for the annual report to discover whether cash improved. It knows cash improved. It is no longer waiting to see whether MTL closes. It closed. It is no longer waiting to see whether the restatement issue will be described in the 10-K. It has been described. What remains is the quality of execution after the reset.

The stock also sits near an important psychological and mechanical area because it trades around the $1 level. That matters for two separate reasons. First, low-priced cannabis tickers can attract retail momentum when policy headlines hit, especially when traders look for liquid symbols tied to Schedule III. Second, extended weakness below $1 can raise exchange-compliance concerns over time, even if no new current non-compliance notice should be assumed unless formally disclosed. The price level is therefore both a sentiment marker and a risk-control marker.

From a sector perspective, CGC remains less economically direct than U.S. multi-state operators for immediate U.S. tax relief, but more liquid and easier for many U.S. retail traders to access. That creates the classic cannabis tension: the cleanest beneficiaries of some reforms may be OTC U.S. operators, while the fastest trade often appears first in liquid Nasdaq names such as $CGC and $TLRY.

The FY2026 Numbers: What Improved and What Did Not

Fiscal 2026 should not be described as a clean breakout year. It was a repair year with visible progress and visible remaining weaknesses. The headline revenue growth is positive, the cannabis segment is improving, cash burn is much lower, and net cash is better. But the company still reported a large net loss, still posted negative adjusted EBITDA, still absorbed impairment and restructuring costs, and still needs to prove that adjusted margins can hold after MTL integration and inventory cleanup.

The good news

The good news is that the company is not simply shrinking. Cannabis net revenue grew, Canadian medical cannabis continued to expand, adult-use cannabis improved for the full year, and free cash outflow was reduced by more than C$100 million versus FY2025. Canopy also ended FY2026 with a much stronger cash balance, helped by financing and recapitalization actions.

The uncomfortable part

The uncomfortable part is that the path remains fragile. Gross margin as reported fell to 12% in Q4 FY2026 from 16% in the prior-year quarter, and full-year gross margin fell to 24% from 30%. The company incurred C$10.7 million of inventory charges in Q4 FY2026, primarily tied to a review of cannabis inventory levels after the MTL Cannabis acquisition. Adjusted gross margin looked better, especially in Q4, but the market will want to see reported margin quality, not only adjusted improvement.

MTL Cannabis: Why the Acquisition Matters

MTL Cannabis is central to the new Canopy story because it gives the company more than just another brand. It gives Canopy a stronger medical platform, additional premium flower capacity, a larger Canadian patient network, cultivation depth, and a more coherent bridge between Canadian supply and international medical demand.

The transaction closed on March 16, 2026. Canopy acquired 100% of MTL’s issued and outstanding shares, issued approximately 41.2 million Canopy common shares and made a cash payment of approximately C$18.5 million as consideration to MTL shareholders. Additional shares were issued to certain former Montreal Cannabis Medical shareholders in exchange for a release of prior obligations, with those shares subject to an 18-month transfer restriction.

Strategically, management highlighted expected run-rate synergies of approximately C$10 million within 18 months. The deal also added MTL’s cultivation and post-harvest assets, Canada House Clinics, Abba Medix, medical cannabis distribution infrastructure, and brands including MTL Cannabis, Low Key by MTL and R’belle. The company described the combined platform as Canada’s leading medical cannabis business by revenue.

The market will not simply accept that as value creation by default. The acquisition introduces integration risk, inventory review charges, potential share resale overhang and the normal danger that synergies arrive slower than promised. But from an operating perspective, it gives Canopy a more credible answer to a key question: where does higher-quality cannabis supply come from, and how does the company support medical demand in Canada and Europe without relying only on legacy brands?

Canada Medical Cannabis: The Core Quality Pillar

If there is one operating area that should receive the most serious attention, it is Canadian medical cannabis. In Q4 FY2026, Canada medical cannabis net revenue increased 27% year over year to C$25.3 million. For FY2026, the segment increased 18% to C$90.8 million. That growth was driven by factors including insured patient growth and a broader assortment of cannabis products offered to customers.

Medical cannabis is important because it is less dependent on the same retail hype cycle that made adult-use cannabis so volatile. It is still regulated, competitive and exposed to reimbursement changes, but it can support a more durable business model if the company can defend patient relationships, maintain quality, improve fulfillment and leverage MTL’s medical infrastructure.

The reimbursement issue should not be ignored. Canopy has specifically discussed pricing actions, product mix refinements and patient retention efforts intended to minimize the impact of reduced medical cannabis reimbursement from Veterans Affairs Canada. That means medical cannabis is not automatically a margin paradise. It is a stronger strategic pillar than commodity adult-use flower, but it still requires disciplined execution.

The real question for FY2027 is whether Canopy can convert Canadian medical leadership into a platform advantage. If medical cannabis grows while adult-use stabilizes and Europe expands, the company can begin to look less like a broken legacy cannabis producer and more like a focused medical-and-consumer platform. If medical growth slows, the FY2027 adjusted EBITDA target becomes harder to believe.

Adult-Use Cannabis: Innovation Helps, But Competition Remains Brutal

Canopy’s Canadian adult-use cannabis business grew 20% for FY2026, reaching C$94.5 million in net revenue. The company pointed to infused pre-roll joints, All-In-One vaporizers and product innovation across categories such as vapes, high-THC flower, pre-rolls and edibles. The launch of DeeLish, with high-THC flower and pre-roll formats, and the continued expansion of Claybourne products show that Canopy is trying to meet the current consumer market where demand actually is rather than where the industry hoped it would be years ago.

The Q4 number was less exciting: Canada adult-use cannabis net revenue increased only 1% year over year to C$20.6 million. That does not erase the full-year growth, but it does show why adult-use remains a difficult base for a turnaround thesis. Consumer cannabis can be promotional, provincial distribution can be uneven, price pressure can be intense, and product cycles can fade quickly.

Claybourne’s Frosted Flyers winning Best Infused Pre-Roll at the 2026 Grow Up Awards gives Canopy a useful brand proof point, and the company expanded the Frosted Flyers lineup with new variety pack formats in June 2026. But awards and product expansions are not enough on their own. The market will measure whether brand momentum translates into repeat revenue, shelf strength, better mix and gross-margin improvement.

The adult-use business therefore belongs in the “watch for proof” category. It can help the turnaround, especially if infused pre-rolls and vapes remain strong categories, but it is not the same quality of revenue as a durable medical platform. The best-case scenario is not just higher adult-use sales; it is higher adult-use sales with better mix and fewer inventory write-downs.

Europe and International Medical Cannabis

Europe is one of the areas where Canopy wants investors to look beyond Canada. In Q4 FY2026, international markets cannabis net revenue increased 68% year over year to C$8.6 million as the company addressed supply-chain challenges in Europe. For the full fiscal year, however, international cannabis revenue declined 7% to C$28.7 million. That contrast is important: the Q4 rebound is encouraging, but FY2026 as a whole still showed the cost of earlier execution constraints.

The May 2026 relaunch of Tweed in Germany with new MTL-derived strains is a concrete example of the post-MTL strategy. Canopy launched Pablo’s Revenge, Dante’z Inferno and Frost’d Flakes under the Tweed brand in Germany and said up to five additional MTL-derived strains were expected to follow in June 2026, with further portfolio expansion planned through the year. Management framed Germany as one of the fastest-growing medical cannabis markets globally and described the European Union as a major long-term opportunity.

This is a potentially meaningful long-term angle, but it should be written carefully. Europe is not a magic switch. Medical cannabis markets differ country by country, reimbursement rules matter, physician adoption matters, and supply consistency matters. Canopy’s advantage is that MTL can support higher-quality flower supply while legacy brands such as Tweed may still have recognition. The risk is that competitors are also pushing into Germany and broader Europe, and regulatory complexity can slow the pace of growth.

For the stock, Europe matters because it can help reposition Canopy away from the damaged Canadian recreational-only narrative. If Germany and other international medical markets grow while Canada medical holds and MTL integration improves supply, the company may earn a more credible medical-cannabis multiple. If Europe disappoints again, the story becomes more dependent on U.S. headlines and retail volatility.

Storz & Bickel: Still Valuable, But No Longer an Easy Growth Anchor

Storz & Bickel remains one of Canopy’s most recognizable non-cannabis-plant-touching assets. It gives the company exposure to vaporization devices, a global premium-device brand and a business that historically carried a stronger margin profile than commodity cannabis. In theory, this should be a quality asset inside the Canopy portfolio.

Fiscal 2026 was not a clean growth year. Storz & Bickel net revenue was C$16.8 million in Q4 FY2026, down 14% year over year, and C$70.7 million for the full year, also down 14%. The company attributed the decline to comparison against strong prior-year sales, continued consumer economic uncertainty and, at the gross-margin level, increased tariffs on imports into the United States and shifts in geographic mix. The new VEAZY vaporizer, launched in September 2025, helped offset pressure but did not fully reverse the segment decline.

The key question is whether Storz & Bickel stabilizes in FY2027. If it does, it can remain an important contributor to gross profit and brand quality. If it keeps shrinking, Canopy loses one of the assets that used to make the story look more differentiated than a pure Canadian cannabis producer.

Canopy USA and the U.S. THC Option

Canopy USA is the part of the story that gives $CGC its U.S. cannabis optionality, but it is also one of the easiest areas for traders to misunderstand. Canopy Growth holds an unconsolidated, non-controlling interest in Canopy USA, LLC. Canopy USA’s portfolio includes exposure to U.S. THC assets such as Acreage, Wana and Jetty-related businesses, subject to the relevant transaction structures, securities exchange limitations and federal permissibility framework.

The simplest way to describe the setup is this: Canopy has a structured economic bridge to U.S. THC, but the bridge is not the same as fully consolidated U.S. cannabis operations inside Canopy Growth’s reported revenue today. That distinction is crucial. A broader Schedule III outcome could improve the value perception of U.S. THC assets, reduce tax pressure for certain cannabis operators and expand investor interest in the sector, but it does not automatically convert CGC into a straightforward U.S. MSO.

This is why the U.S. policy catalyst is powerful but imperfect. If the DEA process progresses favorably, liquid cannabis tickers such as CGC can move quickly because they are easy to trade and recognizable. But from a fundamental perspective, the most direct immediate benefits may still accrue to U.S. operators with plant-touching medical or adult-use businesses, depending on the final rule, tax treatment and legal structure. Canopy’s advantage is liquidity and optionality. Its limitation is complexity.

The correct treatment is not to dismiss Canopy USA, and not to overstate it. It is an option. Options can become valuable when policy regimes change, but they can also remain discounted when timing, legality, exchange rules and consolidation questions remain unresolved.

Schedule III: What It Means for $CGC

The U.S. cannabis rescheduling process is the dominant sector catalyst in mid-2026. The Department of Justice and DEA moved certain FDA-approved marijuana products and state-licensed medical marijuana products into Schedule III in April 2026, while also setting a new administrative hearing on the broader marijuana rescheduling proposal. The broader hearing began on June 29, 2026 and is scheduled to conclude no later than July 15, 2026.

The important editorial distinction is that Schedule III is not federal legalization. Even if marijuana is transferred to Schedule III more broadly, manufacture, distribution, dispensing and possession remain regulated under the Controlled Substances Act and other applicable laws. Schedule III can matter enormously for tax, research, institutional perception and capital-market confidence, but it does not instantly turn the entire U.S. cannabis industry into a normal consumer packaged goods sector.

For CGC, Schedule III matters in three ways. First, it can improve sentiment toward cannabis equities broadly. Second, it can increase perceived value for Canopy USA’s U.S. THC ecosystem. Third, it can bring generalist investors back to a sector that many abandoned after years of dilution, missed promises and weak profitability. But the direct economic effect on Canopy Growth’s consolidated financials is less immediate than the headline reaction might suggest.

This makes CGC a strong trading proxy but a more complex fundamental proxy. The stock can move sharply on Schedule III headlines because it is liquid, visible and historically associated with cannabis reform. Yet the long-term equity value still depends on Canopy’s ability to execute in Canada, Europe, medical cannabis, devices and balance-sheet discipline.

Restatement and Internal Control: Important, But Not the Whole Story

Canopy disclosed in May 2026 that previously issued financial statements for fiscal 2024, fiscal 2025 and certain interim periods should no longer be relied upon because of non-cash technical accounting errors related to certain share-settled warrants with U.S.-dollar exercise prices. The company determined those warrants should have been classified as liabilities rather than equity instruments because of its Canadian-dollar functional currency, with fair value changes recorded through the statement of operations and comprehensive loss.

The company stated that the restatement was expected to be limited to reclassification between equity and liabilities and related fair-value adjustments, all expected to be non-cash. It also said the restatement was not expected to affect revenue, gross margin, operating income or loss, cash flows from operations, adjusted EBITDA, total assets, cash balances, liquidity, covenant compliance or the trajectory of financial performance.

That distinction is important. The restatement does not appear to change the operating story in the same way a revenue recognition issue would. However, it still matters because Canopy expected to report, and the comprehensive annual filing disclosed, a material weakness in internal control over financial reporting. Cannabis investors have already lived through years of weak execution across the sector. Even a technical non-cash restatement can reinforce the market’s desire for cleaner reporting, cleaner structure and fewer surprises.

Capital Structure, Dilution and Runway

Canopy’s improved net cash position is a real positive. At March 31, 2026, the company reported C$364.7 million in cash and cash equivalents, C$16.2 million of current long-term debt, C$217.1 million of long-term debt and total liabilities of C$421.1 million. It also reported 422.1 million common shares issued and outstanding, compared with 183.9 million a year earlier, plus 26.3 million exchangeable shares outstanding.

That share-count increase is not a footnote. It is central to the stock. Canopy has used equity and financing transactions to repair the balance sheet, complete strategic moves and extend runway. That may be necessary, but it also means common shareholders must track dilution carefully. In cannabis, balance-sheet repair often comes with a cost, and that cost is frequently borne by equity holders.

The company also established a US$200 million at-the-market program in August 2025, qualifying the offering of common shares under Canadian and U.S. prospectus supplements. An ATM does not mean shares are automatically sold at once, but it does mean the market must treat future equity issuance as an available financing tool. For a low-priced stock, that can weigh on sentiment during weak periods and cap upside if traders fear supply into rallies.

The positive side is that Canopy’s FY2026 balance sheet is much stronger than the prior-year position. The negative side is that the company still produced negative free cash flow and adjusted EBITDA losses. Until adjusted EBITDA turns positive and cash burn becomes less relevant, dilution risk cannot be removed from the discussion.

Management and Execution

Luc Mongeau’s role as CEO matters because Canopy is trying to reposition itself from cannabis land-grab to disciplined consumer and medical execution. His background is closer to consumer packaged goods, operations and brand management than to the early cannabis entrepreneur narrative. That is the profile Canopy needs if the company wants to be judged on portfolio focus, product mix, supply-chain discipline and cost control rather than on legalization slogans.

The FY2026 commentary from management is clear: Canopy believes it has reset the business, strengthened the balance sheet, acquired MTL Cannabis to drive the next phase of growth, and created a model capable of reaching positive adjusted EBITDA during FY2027. CFO Tom Stewart framed the stronger balance sheet as a way to reduce risk and expand strategic flexibility.

The market will judge management on measurable items. These include gross margin after MTL integration, cannabis segment profitability, Storz & Bickel stabilization, SG&A discipline, international medical supply execution, free cash flow progress and whether the FY2027 adjusted EBITDA target is met without simply leaning on aggressive adjustments.

The leadership additions from MTL also matter. Michael Perron joined as Chief Operating Officer, and MTL co-founders Richard Clément and Michel Clément are serving as strategic advisors to support integration and cultivation. That should help operational execution, but integration still has to be proven in the numbers.

Analyst and Market Expectations

Analyst coverage in cannabis remains uneven and should be treated carefully. MarketWatch data showed a Hold average recommendation for CGC, with eight ratings and a reported average target of approximately US$1.57, with a high target of US$3.58, median target of US$1.17 and low target of US$1.00 around the late-June / early-July 2026 market window. Other aggregators show different counts and target ranges, which is common in low-priced, volatile cannabis equities.

The correct editorial use of these targets is not to treat them as forecasts. They are better understood as a snapshot of how analysts and data vendors frame possible upside and downside under current assumptions. In a stock like CGC, 12-month targets can become stale quickly if the DEA process surprises the market, if management changes guidance, if dilution increases, or if the company misses the FY2027 profitability path.

The more useful question is not whether a target says the stock can move higher. The useful question is what must happen for the market to believe the target. In Canopy’s case, the answer is likely a combination of positive adjusted EBITDA progress, stable or improving cannabis gross margin, better Storz & Bickel performance, reduced cash burn, no new credibility shock from reporting or financing, and a favorable enough U.S. policy backdrop to keep cannabis-sector interest alive.

Timeline of Key Developments

Bull Case

The bull case for Canopy is that the company has finally moved from survival repair to measurable execution. The balance sheet is stronger, free cash outflow is much lower, Canadian medical cannabis is growing, MTL adds strategic depth, Europe can improve from a low base, and management has set a clear FY2027 adjusted EBITDA goal. In a sector where many companies still struggle with leverage, tax pressure, liquidity and investor fatigue, a recognizable Nasdaq-listed cannabis name with net cash and operating momentum can attract attention quickly.

A favorable U.S. policy backdrop would add fuel. If the DEA hearing process keeps Schedule III momentum alive, liquid cannabis tickers can become retail and thematic vehicles again. CGC may not be a direct U.S. operator, but it is one of the most accessible Nasdaq symbols for traders who want cannabis exposure without using OTC MSOs. That liquidity premium can matter during sector rallies.

The strongest version of the bull case is not simply “cannabis goes up.” It is this: Canopy reaches positive adjusted EBITDA during FY2027, MTL integration improves gross margin and supply, Canadian medical cannabis remains a credible growth pillar, Storz & Bickel stabilizes, Europe begins to contribute more consistently, and Canopy USA optionality becomes more valuable under a better U.S. regulatory framework.

Bear Case

The bear case starts with the simple fact that Canopy is still lossmaking. FY2026 net loss from continuing operations was C$262.9 million. Adjusted EBITDA was still negative. Free cash flow was still negative. Gross margin declined on an as-reported basis. Storz & Bickel declined. The company had to restate prior-period financials because of warrant accounting classification. Shares outstanding expanded sharply. Those are not small issues.

The second part of the bear case is that cannabis investors have been disappointed many times before. The sector has repeatedly produced strong narratives, then missed on execution, pricing, margins, legalization timing, profitability and capital discipline. Canopy carries that history more than almost any other ticker because it was one of the symbols of the original cannabis boom.

The third part is that U.S. optionality may remain optional for longer than bullish traders expect. Schedule III is not legalization, legal challenges are possible, recreational cannabis remains politically and legally complex, and Canopy USA is not a simple consolidated revenue engine today. If the market prices CGC as if U.S. reform is immediate and comprehensive, the stock can be vulnerable to disappointment.

Finally, the sub-$1 trading zone can become a pressure point if weakness persists. No new compliance issue should be assumed without a formal disclosure, but the market remembers the 2023 minimum-bid problem and reverse split. For low-priced equities, the psychology of the $1 level can become part of the trade.

Scenario Map

Red Flags to Monitor

How to Read $CGC From Here

The cleanest way to read Canopy Growth from here is to separate the stock into two layers. The first layer is the trading layer: cannabis-policy headlines, DEA hearing developments, Schedule III speculation, sector ETF flows, retail attention and sub-$1 psychology. That layer can move the stock quickly and violently.

The second layer is the operating layer: Canadian medical cannabis, MTL integration, adult-use execution, international medical growth, Storz & Bickel stabilization, cash burn and adjusted EBITDA. That layer moves more slowly, but it determines whether rallies can survive after the headline fades.

A trader may focus on the first layer. A long-term investor should not ignore the second. The problem with cannabis equities over the past several years is that the first layer repeatedly promised what the second layer could not yet deliver. The opportunity in CGC is that the second layer now looks more measurable than it did during the broken part of the cycle. The risk is that it still has not been proven.

Merlintrader Bottom Line

Canopy Growth deserves renewed coverage because the story has changed. The old February 2026 setup was about Q3 numbers, a new CEO and an upcoming Q4 report. The July 2026 setup is about what comes after the reset: FY2026 is now reported, MTL Cannabis is inside the company, the restatement has been disclosed through the comprehensive filing process, cash is stronger, the DEA hearing is underway, and management has committed to the goal of positive adjusted EBITDA during FY2027.

That is a better setup than the old cannabis hype cycle, but it is not a low-risk setup. Canopy still needs to prove that medical growth, adult-use innovation, international expansion and device stabilization can overcome the history of losses, dilution and investor mistrust. The market will not reward hope alone anymore. It may reward proof.

The most useful framework is simple: follow $CGC as a high-volatility cannabis beta name, but judge the company through operational milestones rather than headlines alone. Schedule III can move the ticker. FY2027 execution will decide whether the move has foundation.

Related Merlintrader Reading

• Cannabis Stocks HUB 2026: A Possible Reset for a Broken Sector $MSOS, $TLRY, $CGC, $CRON, $ACB
• DEA Cannabis Hearing Begins: Why Schedule III Still Matters for $TLRY, $CGC and $MSOS
• Tilray Brands (Nasdaq: $TLRY): Cannabis, Beverage and Medical Cannabis Stock Hub
• Cannabis Stocks Watchlist April 2026

Primary Sources and References

• Canopy Growth — Q4 and FY2026 financial results, June 15, 2026
• SEC Form 8-K — non-reliance and restatement disclosure, May 15, 2026
• SEC Comprehensive Form 10-K — FY2026 annual report and restated periods, filed June 15, 2026
• Canopy Growth — strategic recapitalization transactions, January 8, 2026
• Canopy Growth — completion of MTL Cannabis acquisition, March 16, 2026
• Canopy Growth — Tweed relaunch in Germany with MTL strains, May 29, 2026
• Canopy Growth — Claybourne Frosted Flyers award and product expansion, June 8, 2026
• Federal Register — DEA hearing notice on marijuana rescheduling, April 28, 2026
• U.S. Department of Justice — medical marijuana Schedule III order and hearing announcement, April 23, 2026; updated April 24, 2026
• Reuters — cannabis shares reaction to narrower medical-scope rescheduling move, April 23, 2026
• Canopy Growth — US$200 million at-the-market program, August 29, 2025
• MarketWatch — CGC analyst estimates and price target snapshot